Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-11-13

AUTHORS

Vincenzo Mazzaferro, Bassel F. El-Rayes, Michele Droz dit Busset, Christian Cotsoglou, William P. Harris, Nevena Damjanov, Gianluca Masi, Lorenza Rimassa, Nicola Personeni, Fadi Braiteh, Vittorina Zagonel, Kyriakos P. Papadopoulos, Terence Hall, Yunxia Wang, Brian Schwartz, Julia Kazakin, Sherrie Bhoori, Filippo de Braud, Walid L. Shaib

ABSTRACT

BACKGROUND: Next-generation sequencing has identified actionable genetic aberrations in intrahepatic cholangiocarcinomas (iCCA), including the fibroblast growth factor receptor 2 (FGFR2) fusions. Derazantinib (ARQ 087), an orally bioavailable, multi-kinase inhibitor with potent pan-FGFR activity, has shown preliminary therapeutic activity against FGFR2 fusion-positive iCCA. METHODS: This multicentre, phase 1/2, open-label study enrolled adult patients with unresectable iCCA with FGFR2 fusion, who progressed, were intolerant or not eligible to first-line chemotherapy (NCT01752920). Subjects received derazantinib in continuous daily doses. Tumour response was assessed according to RECIST 1.1 every 8 weeks. RESULTS: Twenty-nine patients (18 women/11 men; median age, 58.7 years), 2 treatment-naive and 27 who progressed after at least one prior systemic therapy, were enrolled. Overall response rate was 20.7%, disease control rate was 82.8%. Estimated median progression-free survival was 5.7 months (95% CI: 4.04-9.2 months). Treatment-related adverse events (AE) were observed in 27 patients (93.1%, all grades), including asthenia/fatigue (69.0%), eye toxicity (41.4%), and hyperphosphatemia (75.9%). Grade ≥ 3 AEs occurred in 8 patients (27.6%). CONCLUSION: Derazantinib demonstrated encouraging anti-tumour activity and a manageable safety profile in patients with advanced, unresectable iCCA with FGFR2 fusion who progressed after chemotherapy. A pivotal trial of derazantinib in iCCA is ongoing (NCT03230318). More... »

PAGES

165-171

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41416-018-0334-0

DOI

http://dx.doi.org/10.1038/s41416-018-0334-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1109760959

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30420614


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alkaloids", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholangiocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mutation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Oncogene Proteins, Fusion", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Kinase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptor, Fibroblast Growth Factor, Type 2", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Milan, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.4708.b", 
          "name": [
            "Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy", 
            "University of Milan, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mazzaferro", 
        "givenName": "Vincenzo", 
        "id": "sg:person.0671042612.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671042612.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Winship Cancer Institute, Emory University, Atlanta, GA USA", 
          "id": "http://www.grid.ac/institutes/grid.189967.8", 
          "name": [
            "Winship Cancer Institute, Emory University, Atlanta, GA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "El-Rayes", 
        "givenName": "Bassel F.", 
        "id": "sg:person.010716502757.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010716502757.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Busset", 
        "givenName": "Michele Droz dit", 
        "id": "sg:person.014140151230.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014140151230.80"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cotsoglou", 
        "givenName": "Christian", 
        "id": "sg:person.01264101664.85", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264101664.85"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Seattle Cancer Care Alliance, Seattle, WA USA", 
          "id": "http://www.grid.ac/institutes/grid.430269.a", 
          "name": [
            "Seattle Cancer Care Alliance, Seattle, WA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harris", 
        "givenName": "William P.", 
        "id": "sg:person.0643573106.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643573106.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA USA", 
          "id": "http://www.grid.ac/institutes/grid.25879.31", 
          "name": [
            "Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Damjanov", 
        "givenName": "Nevena", 
        "id": "sg:person.0673235015.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673235015.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, Pisa University Hospital, Pisa, Italy", 
          "id": "http://www.grid.ac/institutes/grid.144189.1", 
          "name": [
            "Department of Oncology, Pisa University Hospital, Pisa, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masi", 
        "givenName": "Gianluca", 
        "id": "sg:person.01062670207.83", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062670207.83"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rimassa", 
        "givenName": "Lorenza", 
        "id": "sg:person.0733441746.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733441746.71"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Biosciences, Humanitas University, Pieve Emanuele, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.452490.e", 
          "name": [
            "Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy", 
            "Department of Medical Biosciences, Humanitas University, Pieve Emanuele, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Personeni", 
        "givenName": "Nicola", 
        "id": "sg:person.01070711603.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070711603.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV USA", 
          "id": "http://www.grid.ac/institutes/grid.428254.d", 
          "name": [
            "Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Braiteh", 
        "givenName": "Fadi", 
        "id": "sg:person.01236270132.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236270132.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Veneto Institute of Oncology IOV - IRCCS, Padua, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419546.b", 
          "name": [
            "Veneto Institute of Oncology IOV - IRCCS, Padua, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zagonel", 
        "givenName": "Vittorina", 
        "id": "sg:person.0622706463.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622706463.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "South Texas Accelerated Research Therapeutics, San Antonio, TX USA", 
          "id": "http://www.grid.ac/institutes/grid.477989.c", 
          "name": [
            "South Texas Accelerated Research Therapeutics, San Antonio, TX USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Papadopoulos", 
        "givenName": "Kyriakos P.", 
        "id": "sg:person.014053222622.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014053222622.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ArQule, Inc, Burlington, MA USA", 
          "id": "http://www.grid.ac/institutes/grid.459379.5", 
          "name": [
            "ArQule, Inc, Burlington, MA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hall", 
        "givenName": "Terence", 
        "id": "sg:person.01100440535.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100440535.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ArQule, Inc, Burlington, MA USA", 
          "id": "http://www.grid.ac/institutes/grid.459379.5", 
          "name": [
            "ArQule, Inc, Burlington, MA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wang", 
        "givenName": "Yunxia", 
        "id": "sg:person.01012457516.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012457516.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ArQule, Inc, Burlington, MA USA", 
          "id": "http://www.grid.ac/institutes/grid.459379.5", 
          "name": [
            "ArQule, Inc, Burlington, MA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartz", 
        "givenName": "Brian", 
        "id": "sg:person.0647410014.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647410014.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "ArQule, Inc, Burlington, MA USA", 
          "id": "http://www.grid.ac/institutes/grid.459379.5", 
          "name": [
            "ArQule, Inc, Burlington, MA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kazakin", 
        "givenName": "Julia", 
        "id": "sg:person.0731202647.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731202647.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bhoori", 
        "givenName": "Sherrie", 
        "id": "sg:person.0775271603.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775271603.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Milan, Milan, Italy", 
          "id": "http://www.grid.ac/institutes/grid.4708.b", 
          "name": [
            "Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy", 
            "University of Milan, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Braud", 
        "givenName": "Filippo", 
        "id": "sg:person.011747771717.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011747771717.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Winship Cancer Institute, Emory University, Atlanta, GA USA", 
          "id": "http://www.grid.ac/institutes/grid.189967.8", 
          "name": [
            "Winship Cancer Institute, Emory University, Atlanta, GA USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shaib", 
        "givenName": "Walid L.", 
        "id": "sg:person.01067005334.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067005334.40"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrclinonc.2017.157", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092133630", 
          "https://doi.org/10.1038/nrclinonc.2017.157"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd.2015.9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013850621", 
          "https://doi.org/10.1038/nrd.2015.9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncomms7087", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022244232", 
          "https://doi.org/10.1038/ncomms7087"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2017.330", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092053554", 
          "https://doi.org/10.1038/bjc.2017.330"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11864-016-0432-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040871394", 
          "https://doi.org/10.1007/s11864-016-0432-2"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11-13", 
    "datePublishedReg": "2018-11-13", 
    "description": "BACKGROUND: Next-generation sequencing has identified actionable genetic aberrations in intrahepatic cholangiocarcinomas (iCCA), including the fibroblast growth factor receptor 2 (FGFR2) fusions. Derazantinib (ARQ 087), an orally bioavailable, multi-kinase inhibitor with potent pan-FGFR activity, has shown preliminary therapeutic activity against FGFR2 fusion-positive iCCA.\nMETHODS: This multicentre, phase 1/2, open-label study enrolled adult patients with unresectable iCCA with FGFR2 fusion, who progressed, were intolerant or not eligible to first-line chemotherapy (NCT01752920). Subjects received derazantinib in continuous daily doses. Tumour response was assessed according to RECIST 1.1 every 8 weeks.\nRESULTS: Twenty-nine patients (18 women/11 men; median age, 58.7 years), 2 treatment-naive and 27 who progressed after at least one prior systemic therapy, were enrolled. Overall response rate was 20.7%, disease control rate was 82.8%. Estimated median progression-free survival was 5.7 months (95% CI: 4.04-9.2 months). Treatment-related adverse events (AE) were observed in 27 patients (93.1%, all grades), including asthenia/fatigue (69.0%), eye toxicity (41.4%), and hyperphosphatemia (75.9%). Grade\u2009\u2265\u20093 AEs occurred in 8 patients (27.6%).\nCONCLUSION: Derazantinib demonstrated encouraging anti-tumour activity and a manageable safety profile in patients with advanced, unresectable iCCA with FGFR2 fusion who progressed after chemotherapy. A pivotal trial of derazantinib in iCCA is ongoing (NCT03230318).", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41416-018-0334-0", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1017082", 
        "issn": [
          "0007-0920", 
          "1532-1827"
        ], 
        "name": "British Journal of Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "120"
      }
    ], 
    "keywords": [
      "unresectable intrahepatic cholangiocarcinoma", 
      "intrahepatic cholangiocarcinoma", 
      "adverse events", 
      "FGFR2 fusions", 
      "fibroblast growth factor receptor 2 (FGFR2) fusions", 
      "median progression-free survival", 
      "treatment-related adverse events", 
      "encouraging anti-tumor activity", 
      "actionable genetic aberrations", 
      "continuous daily doses", 
      "prior systemic therapy", 
      "disease control rate", 
      "asthenia/fatigue", 
      "manageable safety profile", 
      "open-label study", 
      "first-line chemotherapy", 
      "progression-free survival", 
      "overall response rate", 
      "multi-kinase inhibitor", 
      "anti-tumor activity", 
      "RECIST 1.1", 
      "phase 1/2", 
      "adult patients", 
      "systemic therapy", 
      "pivotal trials", 
      "daily doses", 
      "safety profile", 
      "control rate", 
      "eye toxicity", 
      "patients", 
      "response rate", 
      "therapeutic activity", 
      "genetic aberrations", 
      "next-generation sequencing", 
      "chemotherapy", 
      "cholangiocarcinoma", 
      "multicentre", 
      "hyperphosphatemia", 
      "therapy", 
      "doses", 
      "activity", 
      "trials", 
      "weeks", 
      "months", 
      "survival", 
      "inhibitors", 
      "toxicity", 
      "subjects", 
      "rate", 
      "grade", 
      "aberrations", 
      "fatigue", 
      "fusion", 
      "response", 
      "sequencing", 
      "study", 
      "events", 
      "profile", 
      "growth factor receptor 2 (FGFR2) fusions", 
      "factor receptor 2 (FGFR2) fusions", 
      "receptor 2 (FGFR2) fusions", 
      "Derazantinib", 
      "potent pan-FGFR activity", 
      "pan-FGFR activity", 
      "preliminary therapeutic activity", 
      "FGFR2 fusion-positive iCCA", 
      "fusion-positive iCCA", 
      "inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma", 
      "FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma", 
      "gene fusion-positive intrahepatic cholangiocarcinoma"
    ], 
    "name": "Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma", 
    "pagination": "165-171", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1109760959"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41416-018-0334-0"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30420614"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41416-018-0334-0", 
      "https://app.dimensions.ai/details/publication/pub.1109760959"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_786.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41416-018-0334-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0334-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0334-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0334-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41416-018-0334-0'


 

This table displays all metadata directly associated to this object as RDF triples.

369 TRIPLES      22 PREDICATES      115 URIs      102 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41416-018-0334-0 schema:about N18993cf8652b4fa1a70f68b4ea2af929
2 N2682edd4f13d488a9283a161e7b79bbe
3 N6f10d97b369048598179ab5ed25dcc2a
4 N7abfa9cd2cfd4925aef370f56981a0a5
5 N84ea3204650f40a2b91fd2d0f374169f
6 N91a959daac00413b99dd4aa38bcf1d6c
7 N97dfa55683bf4394ae1917495e83d0aa
8 Nabda8b85fbbb490596fa1bc23433b104
9 Nbe3f3897f60e469aa4d52f7629a3506d
10 Nc3708a9f88d64a98b3fd3208ba7ec1e2
11 Nc5a1e138b42240d78c715d9eb93e84aa
12 Ncbf97295b8094ee7b5b545d14cadbdcc
13 Ne7d49eb9589441dc988437974c10ccfb
14 Nf6b15d7e97504de1b3e9fdb8f87f00a9
15 anzsrc-for:11
16 anzsrc-for:1112
17 schema:author N4be053cac5234586ab3a600e71e376e7
18 schema:citation sg:pub.10.1007/s11864-016-0432-2
19 sg:pub.10.1038/bjc.2017.330
20 sg:pub.10.1038/ncomms7087
21 sg:pub.10.1038/nrclinonc.2017.157
22 sg:pub.10.1038/nrd.2015.9
23 schema:datePublished 2018-11-13
24 schema:datePublishedReg 2018-11-13
25 schema:description BACKGROUND: Next-generation sequencing has identified actionable genetic aberrations in intrahepatic cholangiocarcinomas (iCCA), including the fibroblast growth factor receptor 2 (FGFR2) fusions. Derazantinib (ARQ 087), an orally bioavailable, multi-kinase inhibitor with potent pan-FGFR activity, has shown preliminary therapeutic activity against FGFR2 fusion-positive iCCA. METHODS: This multicentre, phase 1/2, open-label study enrolled adult patients with unresectable iCCA with FGFR2 fusion, who progressed, were intolerant or not eligible to first-line chemotherapy (NCT01752920). Subjects received derazantinib in continuous daily doses. Tumour response was assessed according to RECIST 1.1 every 8 weeks. RESULTS: Twenty-nine patients (18 women/11 men; median age, 58.7 years), 2 treatment-naive and 27 who progressed after at least one prior systemic therapy, were enrolled. Overall response rate was 20.7%, disease control rate was 82.8%. Estimated median progression-free survival was 5.7 months (95% CI: 4.04-9.2 months). Treatment-related adverse events (AE) were observed in 27 patients (93.1%, all grades), including asthenia/fatigue (69.0%), eye toxicity (41.4%), and hyperphosphatemia (75.9%). Grade ≥ 3 AEs occurred in 8 patients (27.6%). CONCLUSION: Derazantinib demonstrated encouraging anti-tumour activity and a manageable safety profile in patients with advanced, unresectable iCCA with FGFR2 fusion who progressed after chemotherapy. A pivotal trial of derazantinib in iCCA is ongoing (NCT03230318).
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree true
29 schema:isPartOf Ne71355354f8f45f09508ce3b739b752a
30 Nf94d9ff8fa804ece899ff62f4cf36820
31 sg:journal.1017082
32 schema:keywords Derazantinib
33 FGFR2 fusion-positive iCCA
34 FGFR2 fusions
35 FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
36 RECIST 1.1
37 aberrations
38 actionable genetic aberrations
39 activity
40 adult patients
41 adverse events
42 anti-tumor activity
43 asthenia/fatigue
44 chemotherapy
45 cholangiocarcinoma
46 continuous daily doses
47 control rate
48 daily doses
49 disease control rate
50 doses
51 encouraging anti-tumor activity
52 events
53 eye toxicity
54 factor receptor 2 (FGFR2) fusions
55 fatigue
56 fibroblast growth factor receptor 2 (FGFR2) fusions
57 first-line chemotherapy
58 fusion
59 fusion-positive iCCA
60 gene fusion-positive intrahepatic cholangiocarcinoma
61 genetic aberrations
62 grade
63 growth factor receptor 2 (FGFR2) fusions
64 hyperphosphatemia
65 inhibitors
66 inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
67 intrahepatic cholangiocarcinoma
68 manageable safety profile
69 median progression-free survival
70 months
71 multi-kinase inhibitor
72 multicentre
73 next-generation sequencing
74 open-label study
75 overall response rate
76 pan-FGFR activity
77 patients
78 phase 1/2
79 pivotal trials
80 potent pan-FGFR activity
81 preliminary therapeutic activity
82 prior systemic therapy
83 profile
84 progression-free survival
85 rate
86 receptor 2 (FGFR2) fusions
87 response
88 response rate
89 safety profile
90 sequencing
91 study
92 subjects
93 survival
94 systemic therapy
95 therapeutic activity
96 therapy
97 toxicity
98 treatment-related adverse events
99 trials
100 unresectable intrahepatic cholangiocarcinoma
101 weeks
102 schema:name Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma
103 schema:pagination 165-171
104 schema:productId N867e8d4eeef74d07927160ca9714b034
105 Na54f29e7f83b4e50a9df65132f8c2d10
106 Ncbbfa93b4c644433a295e3aa29551ba9
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1109760959
108 https://doi.org/10.1038/s41416-018-0334-0
109 schema:sdDatePublished 2021-12-01T19:41
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N6eb9dcc85d0742ec92987bb8fddbf954
112 schema:url https://doi.org/10.1038/s41416-018-0334-0
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N18993cf8652b4fa1a70f68b4ea2af929 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Male
118 rdf:type schema:DefinedTerm
119 N191f8f27650b413c8ec60b2b7e73218f rdf:first sg:person.01264101664.85
120 rdf:rest N2b1ccd5e84bd440f867f03e599e2b703
121 N2682edd4f13d488a9283a161e7b79bbe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Humans
123 rdf:type schema:DefinedTerm
124 N2b1ccd5e84bd440f867f03e599e2b703 rdf:first sg:person.0643573106.13
125 rdf:rest N765372c1e3a14ed89e66419631fb57ae
126 N327f5b95ce39431d85ee23c72706aeae rdf:first sg:person.0733441746.71
127 rdf:rest N790dfb7ee8c847b28ea17dbf356e7b67
128 N3a53250554ce41e1bf1707254aed972e rdf:first sg:person.0775271603.25
129 rdf:rest N42c88e2721ac48cc9f41e017479a4fee
130 N42c88e2721ac48cc9f41e017479a4fee rdf:first sg:person.011747771717.20
131 rdf:rest N6431547e5df44f29aa9ae5e161d6d3ff
132 N4be053cac5234586ab3a600e71e376e7 rdf:first sg:person.0671042612.13
133 rdf:rest Na68798e8834648a8b2f28e51ae37f28a
134 N571646e873a34196b383c9a320994b35 rdf:first sg:person.014053222622.27
135 rdf:rest Na85ed739fa514d70be3592635ac7a16e
136 N6431547e5df44f29aa9ae5e161d6d3ff rdf:first sg:person.01067005334.40
137 rdf:rest rdf:nil
138 N64fb3bb227864bf5923fa871870b1712 rdf:first sg:person.0731202647.44
139 rdf:rest N3a53250554ce41e1bf1707254aed972e
140 N6b3332bbcc8e4e4f880264b919ce47d6 rdf:first sg:person.01012457516.41
141 rdf:rest Nffa5aa5961144ca28252497e40db0055
142 N6eb9dcc85d0742ec92987bb8fddbf954 schema:name Springer Nature - SN SciGraph project
143 rdf:type schema:Organization
144 N6f10d97b369048598179ab5ed25dcc2a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Receptor, Fibroblast Growth Factor, Type 2
146 rdf:type schema:DefinedTerm
147 N765372c1e3a14ed89e66419631fb57ae rdf:first sg:person.0673235015.16
148 rdf:rest Nb9020cadd6f54761bb32c09348b3cbe3
149 N790dfb7ee8c847b28ea17dbf356e7b67 rdf:first sg:person.01070711603.65
150 rdf:rest N9a5ad141a79743ab8536734f7a9969c2
151 N7abfa9cd2cfd4925aef370f56981a0a5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Female
153 rdf:type schema:DefinedTerm
154 N84ea3204650f40a2b91fd2d0f374169f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Aged
156 rdf:type schema:DefinedTerm
157 N867e8d4eeef74d07927160ca9714b034 schema:name doi
158 schema:value 10.1038/s41416-018-0334-0
159 rdf:type schema:PropertyValue
160 N91a959daac00413b99dd4aa38bcf1d6c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Adult
162 rdf:type schema:DefinedTerm
163 N97dfa55683bf4394ae1917495e83d0aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Oncogene Proteins, Fusion
165 rdf:type schema:DefinedTerm
166 N9a5ad141a79743ab8536734f7a9969c2 rdf:first sg:person.01236270132.09
167 rdf:rest Nc647db0121e840abafb433fb736fefaa
168 Na54f29e7f83b4e50a9df65132f8c2d10 schema:name dimensions_id
169 schema:value pub.1109760959
170 rdf:type schema:PropertyValue
171 Na68798e8834648a8b2f28e51ae37f28a rdf:first sg:person.010716502757.79
172 rdf:rest Nda9686cc6a394c2bb492c23dd5e22358
173 Na85ed739fa514d70be3592635ac7a16e rdf:first sg:person.01100440535.01
174 rdf:rest N6b3332bbcc8e4e4f880264b919ce47d6
175 Nabda8b85fbbb490596fa1bc23433b104 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Alkaloids
177 rdf:type schema:DefinedTerm
178 Nb9020cadd6f54761bb32c09348b3cbe3 rdf:first sg:person.01062670207.83
179 rdf:rest N327f5b95ce39431d85ee23c72706aeae
180 Nbe3f3897f60e469aa4d52f7629a3506d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Middle Aged
182 rdf:type schema:DefinedTerm
183 Nc3708a9f88d64a98b3fd3208ba7ec1e2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Clinical Trials as Topic
185 rdf:type schema:DefinedTerm
186 Nc5a1e138b42240d78c715d9eb93e84aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Protein Kinase Inhibitors
188 rdf:type schema:DefinedTerm
189 Nc647db0121e840abafb433fb736fefaa rdf:first sg:person.0622706463.81
190 rdf:rest N571646e873a34196b383c9a320994b35
191 Ncbbfa93b4c644433a295e3aa29551ba9 schema:name pubmed_id
192 schema:value 30420614
193 rdf:type schema:PropertyValue
194 Ncbf97295b8094ee7b5b545d14cadbdcc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Cholangiocarcinoma
196 rdf:type schema:DefinedTerm
197 Nda9686cc6a394c2bb492c23dd5e22358 rdf:first sg:person.014140151230.80
198 rdf:rest N191f8f27650b413c8ec60b2b7e73218f
199 Ne71355354f8f45f09508ce3b739b752a schema:issueNumber 2
200 rdf:type schema:PublicationIssue
201 Ne7d49eb9589441dc988437974c10ccfb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Mutation
203 rdf:type schema:DefinedTerm
204 Nf6b15d7e97504de1b3e9fdb8f87f00a9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
205 schema:name Aged, 80 and over
206 rdf:type schema:DefinedTerm
207 Nf94d9ff8fa804ece899ff62f4cf36820 schema:volumeNumber 120
208 rdf:type schema:PublicationVolume
209 Nffa5aa5961144ca28252497e40db0055 rdf:first sg:person.0647410014.27
210 rdf:rest N64fb3bb227864bf5923fa871870b1712
211 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
212 schema:name Medical and Health Sciences
213 rdf:type schema:DefinedTerm
214 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
215 schema:name Oncology and Carcinogenesis
216 rdf:type schema:DefinedTerm
217 sg:journal.1017082 schema:issn 0007-0920
218 1532-1827
219 schema:name British Journal of Cancer
220 schema:publisher Springer Nature
221 rdf:type schema:Periodical
222 sg:person.01012457516.41 schema:affiliation grid-institutes:grid.459379.5
223 schema:familyName Wang
224 schema:givenName Yunxia
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012457516.41
226 rdf:type schema:Person
227 sg:person.01062670207.83 schema:affiliation grid-institutes:grid.144189.1
228 schema:familyName Masi
229 schema:givenName Gianluca
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01062670207.83
231 rdf:type schema:Person
232 sg:person.01067005334.40 schema:affiliation grid-institutes:grid.189967.8
233 schema:familyName Shaib
234 schema:givenName Walid L.
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01067005334.40
236 rdf:type schema:Person
237 sg:person.01070711603.65 schema:affiliation grid-institutes:grid.452490.e
238 schema:familyName Personeni
239 schema:givenName Nicola
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01070711603.65
241 rdf:type schema:Person
242 sg:person.010716502757.79 schema:affiliation grid-institutes:grid.189967.8
243 schema:familyName El-Rayes
244 schema:givenName Bassel F.
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010716502757.79
246 rdf:type schema:Person
247 sg:person.01100440535.01 schema:affiliation grid-institutes:grid.459379.5
248 schema:familyName Hall
249 schema:givenName Terence
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01100440535.01
251 rdf:type schema:Person
252 sg:person.011747771717.20 schema:affiliation grid-institutes:grid.4708.b
253 schema:familyName de Braud
254 schema:givenName Filippo
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011747771717.20
256 rdf:type schema:Person
257 sg:person.01236270132.09 schema:affiliation grid-institutes:grid.428254.d
258 schema:familyName Braiteh
259 schema:givenName Fadi
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01236270132.09
261 rdf:type schema:Person
262 sg:person.01264101664.85 schema:affiliation grid-institutes:None
263 schema:familyName Cotsoglou
264 schema:givenName Christian
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01264101664.85
266 rdf:type schema:Person
267 sg:person.014053222622.27 schema:affiliation grid-institutes:grid.477989.c
268 schema:familyName Papadopoulos
269 schema:givenName Kyriakos P.
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014053222622.27
271 rdf:type schema:Person
272 sg:person.014140151230.80 schema:affiliation grid-institutes:None
273 schema:familyName Busset
274 schema:givenName Michele Droz dit
275 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014140151230.80
276 rdf:type schema:Person
277 sg:person.0622706463.81 schema:affiliation grid-institutes:grid.419546.b
278 schema:familyName Zagonel
279 schema:givenName Vittorina
280 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0622706463.81
281 rdf:type schema:Person
282 sg:person.0643573106.13 schema:affiliation grid-institutes:grid.430269.a
283 schema:familyName Harris
284 schema:givenName William P.
285 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0643573106.13
286 rdf:type schema:Person
287 sg:person.0647410014.27 schema:affiliation grid-institutes:grid.459379.5
288 schema:familyName Schwartz
289 schema:givenName Brian
290 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0647410014.27
291 rdf:type schema:Person
292 sg:person.0671042612.13 schema:affiliation grid-institutes:grid.4708.b
293 schema:familyName Mazzaferro
294 schema:givenName Vincenzo
295 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671042612.13
296 rdf:type schema:Person
297 sg:person.0673235015.16 schema:affiliation grid-institutes:grid.25879.31
298 schema:familyName Damjanov
299 schema:givenName Nevena
300 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0673235015.16
301 rdf:type schema:Person
302 sg:person.0731202647.44 schema:affiliation grid-institutes:grid.459379.5
303 schema:familyName Kazakin
304 schema:givenName Julia
305 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731202647.44
306 rdf:type schema:Person
307 sg:person.0733441746.71 schema:affiliation grid-institutes:grid.417728.f
308 schema:familyName Rimassa
309 schema:givenName Lorenza
310 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0733441746.71
311 rdf:type schema:Person
312 sg:person.0775271603.25 schema:affiliation grid-institutes:None
313 schema:familyName Bhoori
314 schema:givenName Sherrie
315 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0775271603.25
316 rdf:type schema:Person
317 sg:pub.10.1007/s11864-016-0432-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040871394
318 https://doi.org/10.1007/s11864-016-0432-2
319 rdf:type schema:CreativeWork
320 sg:pub.10.1038/bjc.2017.330 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092053554
321 https://doi.org/10.1038/bjc.2017.330
322 rdf:type schema:CreativeWork
323 sg:pub.10.1038/ncomms7087 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022244232
324 https://doi.org/10.1038/ncomms7087
325 rdf:type schema:CreativeWork
326 sg:pub.10.1038/nrclinonc.2017.157 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092133630
327 https://doi.org/10.1038/nrclinonc.2017.157
328 rdf:type schema:CreativeWork
329 sg:pub.10.1038/nrd.2015.9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013850621
330 https://doi.org/10.1038/nrd.2015.9
331 rdf:type schema:CreativeWork
332 grid-institutes:None schema:alternateName Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy
333 schema:name Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy
334 rdf:type schema:Organization
335 grid-institutes:grid.144189.1 schema:alternateName Department of Oncology, Pisa University Hospital, Pisa, Italy
336 schema:name Department of Oncology, Pisa University Hospital, Pisa, Italy
337 rdf:type schema:Organization
338 grid-institutes:grid.189967.8 schema:alternateName Winship Cancer Institute, Emory University, Atlanta, GA USA
339 schema:name Winship Cancer Institute, Emory University, Atlanta, GA USA
340 rdf:type schema:Organization
341 grid-institutes:grid.25879.31 schema:alternateName Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA USA
342 schema:name Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA USA
343 rdf:type schema:Organization
344 grid-institutes:grid.417728.f schema:alternateName Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
345 schema:name Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
346 rdf:type schema:Organization
347 grid-institutes:grid.419546.b schema:alternateName Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
348 schema:name Veneto Institute of Oncology IOV - IRCCS, Padua, Italy
349 rdf:type schema:Organization
350 grid-institutes:grid.428254.d schema:alternateName Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV USA
351 schema:name Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV USA
352 rdf:type schema:Organization
353 grid-institutes:grid.430269.a schema:alternateName Seattle Cancer Care Alliance, Seattle, WA USA
354 schema:name Seattle Cancer Care Alliance, Seattle, WA USA
355 rdf:type schema:Organization
356 grid-institutes:grid.452490.e schema:alternateName Department of Medical Biosciences, Humanitas University, Pieve Emanuele, Milan, Italy
357 schema:name Department of Medical Biosciences, Humanitas University, Pieve Emanuele, Milan, Italy
358 Humanitas Cancer Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy
359 rdf:type schema:Organization
360 grid-institutes:grid.459379.5 schema:alternateName ArQule, Inc, Burlington, MA USA
361 schema:name ArQule, Inc, Burlington, MA USA
362 rdf:type schema:Organization
363 grid-institutes:grid.4708.b schema:alternateName University of Milan, Milan, Italy
364 schema:name Department of Surgery and Oncology, Istituto Nazionale Tumori IRCCS, Milan, Italy
365 University of Milan, Milan, Italy
366 rdf:type schema:Organization
367 grid-institutes:grid.477989.c schema:alternateName South Texas Accelerated Research Therapeutics, San Antonio, TX USA
368 schema:name South Texas Accelerated Research Therapeutics, San Antonio, TX USA
369 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...